PCRX Pacira BioSciences, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Innovative non-opioid pain therapies including EXPAREL, ZILRETTA, and iovera° for postsurgical and osteoarthritis pain management
• • New strategic plan "5x30" launched in Jan 2025 targeting 3M+ patients, double-digit revenue CAGR, 5% gross margin improvement, 5 clinical programs, 5 partnerships by 2030
• • 2025 acquisition of GQ Bio Therapeutics expanding pipeline with gene therapy (PCRX-201) for osteoarthritis in Phase 2 development
• • Net sales growth: EXPAREL $575.1M (2025) up from $549.0M (2024), ZILRETTA steady ~$117M, iovera° sales increased to $24.2M in 2025
• • FDA approved label expansion for EXPAREL in Nov 2023 adding adductor canal and sciatic nerve blocks, broadening usage for over 3 million lower extremity procedures annually

Risk Factors

• • Ongoing patent litigation against WhiteOak and Qilu threatens exclusive rights to EXPAREL and ZILRETTA, risking loss of patent protection and regulatory exclusivity
• • Significant revenue concentration with EXPAREL at 79% and ZILRETTA at 16% of total 2025 revenue, exposing the company to commercial risks in these products
• • Dependence on third-party cold-chain distributors for EXPAREL risks product spoilage if temperature controls fail, with limited insurance coverage for losses
• • Intense competition from generic opioids and immediate-release steroids, including established generics for OA pain, may limit market share and pricing power
• • Commercial success depends on obtaining timely hospital formulary approvals and physician prescribing, with delays or restrictions potentially reducing revenues

Management Discussion & Analysis

• • Revenue $726.4M, up 4% YoY from $701.0M; EXPAREL $575.1M (+5%), ZILRETTA $116.6M (-1%), iovera° $24.2M (+6%)
• • Gross margin 79% in 2025 vs 76% in 2024; cost of goods sold declined 12% to $149.7M
• • Best segment: EXPAREL sales $575.1M (+5%), worst: ZILRETTA sales $116.6M (-1%)
• • Cash used for share repurchases: $50M for 2 million shares in Q4 2025; no dividend or capex specifics disclosed
• • 2026 outlook: Expanded Asian-Pacific access via LG Chem partnership with $2M upfront; tariff risks mitigated by recent US Supreme Court ruling; ongoing challenges from generic litigation and investment in R&D (44% increase)

What are the latest PCRX SEC filings in 2026?

Pacira BioSciences, Inc. (PCRX) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PCRX file its most recent 10-K annual report?

Pacira BioSciences, Inc. (PCRX) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PCRX 10-Q quarterly reports?

Pacira BioSciences, Inc. (PCRX)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every PCRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PCRX filed recently?

Pacira BioSciences, Inc. (PCRX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PCRX insider trading activity (Form 4)?

SignalX aggregates every PCRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PCRX file with the SEC?

Pacira BioSciences, Inc. (PCRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PCRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Pacira BioSciences, Inc. (PCRX).

What is PCRX's SEC CIK number?

Pacira BioSciences, Inc. (PCRX)'s SEC CIK (Central Index Key) number is 1396814. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1396814 to look up all PCRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PCRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Pacira BioSciences, Inc. (PCRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.